Drug Interactions between betrixaban and temsirolimus
This report displays the potential drug interactions for the following 2 drugs:
- betrixaban
- temsirolimus
Interactions between your drugs
temsirolimus betrixaban
Applies to: temsirolimus and betrixaban
MONITOR CLOSELY: According to the package labeling, patients receiving temsirolimus in combination with anticoagulation therapy may be at increased risk of developing intracerebral bleeding, including fatal outcomes. The mechanism of interaction has not been described.
MANAGEMENT: Patients receiving anticoagulants should be informed of the increased risk of developing intracerebral bleeding while on temsirolimus.
References (1)
- (2007) "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories
Drug and food interactions
temsirolimus food
Applies to: temsirolimus
GENERALLY AVOID: Coadministration of temsirolimus with grapefruit juice may increase the plasma concentrations of sirolimus, a major active metabolite of temsirolimus and known substrate of CYP450 3A4. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism by certain compounds present in grapefruits.
MANAGEMENT: Patients treated with temsirolimus should preferably avoid the consumption of grapefruit or grapefruit juice.
References (1)
- (2007) "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories
betrixaban food
Applies to: betrixaban
ADJUST DOSING INTERVAL: Food reduces the oral bioavailability of betrixaban. When administered with a low-fat (900 calories; 20% fat) or high-fat (900 calories; 60% fat) meal, betrixaban peak plasma concentration (Cmax) and systemic exposure (AUC) decreased relative to administration in the fasting state by an average of 70% and 61%, respectively, with the low-fat meal and 50% and 48%, respectively, with the high-fat meal. The effect of food on betrixaban pharmacokinetics could be observed for up to 6 hours after meal intake.
MANAGEMENT: The manufacturer recommends taking betrixaban at the same time each day with food.
References (1)
- (2017) "Product Information. Bevyxxa (betrixaban)." Portola Pharmaceuticals
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.